CHM's Pharmacovigilance Expert Advisory Group (PEAG)

The Commission on Human Medicines (CHM) is looking to appoint one expert to the Pharmacovigilance Expert Advisory Group (PEAG).

The PEAG advises the CHM on all aspects of pharmacovigilance for human medicines (including herbal products) and vaccines. Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine-related problem.

The PEAG advises the CHM on the public health importance of potential new safety signals; the confirmation of identified risks and their size and nature; how the risks should be managed including healthcare professional, patient and public communications; risk management planning for new and novel medicinal products; the design and progress of safety studies and analysis of the results; and methodologies for pharmacovigilance.

The PEAG also advises the CHM and the Medicines and Healthcare products Regulatory Agency (MHRA)on the strategic direction of the Yellow Card Scheme - the UK system for collecting and monitoring information on suspected adverse effects and medicine-related safety concerns, and provides advice to MHRA on public applications for access to Yellow Card data for scientific research.

We are looking for an experienced medical practitioner who can provide their specialisms perspective on relevant UK clinical practice and medicine-related matters. The applicant must be a practising physician, preferably with an interest in medicines management and patient safety.

The Member must be able to demonstrate the qualities, skills and experience to meet all the essential criteria for appointment.

The Medicines and Healthcare products Regulatory Agency enhance and improve the health of millions of people every day through the effective regulation of medicines and medical devices, underpinned by science and research.